Grant Approval

Futura Medical PLC
27 July 2007




For immediate release                                              27 July 2007



                               Futura Medical Plc

                          ('Futura' or 'the Company')

             Receives £200,000 SEEDA grant for DermaSys(R) product



Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for the consumer healthcare market, is pleased to announce that it has
been awarded a Grant for Research & Development of £200,000 from the South East
England Development Agency (SEEDA) to support the development of a pipeline
product that uses the Company's novel DermaSys(R) trans-dermal delivery
technology.



SEEDA, the Regional Development Agency responsible for the sustainable economic
development of the South East of England, awarded the grant after a thorough
review of the application to develop a specific product in relation to the
DermaSys(R) technology.  The Grant for the R&D scheme is a Department of
Innovation, Universities and Skills (DIUS) national programme, where grants are
awarded following assessment of the potential to achieve a technological advance
in a new product or process.



Jeff Alexander, SEEDA Executive Director for Global Competitiveness, said: 'I
wish Futura Medical every success with the development of this product using the
DermaSys(R) technology.  SEEDA's Grant for Research & Development scheme is
designed to assist this kind of innovative product development.'



James Barder, Futura Medical's Chief Executive, said: 'We are delighted to have
been awarded this grant from SEEDA, which represents a further endorsement to
develop both the technical and commercial qualities of our DermaSys(R) drug
delivery technology.'



DermaSys(R) is the brand name for Futura's versatile gel technology for the
rapid delivery of drugs through the skin, which the Company is continuing to
assess against a wide range of generic drugs suited to topical delivery.





For any further information please contact:

 Futura Medical plc
 James Barder, Chief Executive                        Tel: [phone]
 mail to: [e-mail]              www.futuramedical.co.uk


 Canaccord Adams                                      Tel: [phone]
 Mark Ashurst



For any media enquiries please contact:

 Buchanan Communications                             Tel: [phone]
 Mark Court / Rebecca Dietrich



Notes



Futura Medical plc



Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare.  The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.



Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.



www.futuramedical.co.uk


About SEEDA



The South East England Development Agency (SEEDA) is the Government funded
Agency responsible for the sustainable economic development of the South East of
England - the driving force of the UK's economy. Our aim is to create a
prosperous, dynamic and inspirational region by helping businesses compete more
effectively, training a highly skilled workforce, supporting and enabling our
communities while safeguarding our natural resources and cherishing our rich
cultural heritage.



The Regional Economic Strategy (RES) for South East England 2006 -2016: a world
class region achieving sustainable prosperity, has three headline targets:



Global Competitiveness: Achieving an average annual increase in GVA (Gross Value
Added) per capita of at least 3%.



Smart Growth: Increasing productivity per worker by an average 2.4% annually,
from £39,000 in 2005 to at least £50,000 by 2016 (in constant prices).



Sustainable Prosperity: Reducing the rate of increase in the region's ecological
footprint (from 6.3 global hectares per capita in 2003, currently increasing at
1.1% per capita per annum), stabilizing it and seek to reduce it by 2016.



For further press information please contact: Francesca Fogell, SEEDA Marketing
& PR Manager, tel, 01483 484275, email, [e-mail]



www.seeda.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange